在长期输血治疗过程中,全身的铁过荷将会影响到很多组织,这是临床中相当熟悉的情况。如果脏器还没有变质性病变,就不必给予特殊的考虑,但若铁过荷的毒性已使心肌、肝脏和内分泌器官变质,则常因心、肝功能衰竭而导致死亡。1963年,有人用去铁敏进行铁螯合剂疗法排除铁过荷患者体内的铁,但是直到1974年Barry等人对纯合子型β-地中海贫血病人的研究才获得明确的证据:通过肠外途径长期给予去铁敏可使肝内铁浓度下降。从这项研究中 In the long-term blood transfusion treatment, the whole body of iron overload will affect many tissues, which is quite familiar with the clinical situation. If the organ has not yet degenerative lesions, do not give special consideration, but if the iron overload of the toxicity of the heart muscle, liver and endocrine organ spoilage, often due to heart and liver failure and death. In 1963, iron-chelating therapy was used to eliminate iron in patients with iron overload, but until about Barry et al.’s study of homozygous β-thalassemia patients in 1974, clear evidence was obtained: by the parenteral route Long-term administration of deferoxamine can reduce intrahepatic iron concentrations. From this research